Kris Jenner and Ozempic: what celebrity use actually tells us
Quick answer
Kris Jenner describes a single trial of semaglutide that produced significant nausea and functional impairment, a well-documented side effect affecting up to 44% of users in clinical trials, followed by a switch to an unspecified peptide injection under physician guidance. The clinical takeaway is that GLP-1 intolerance exists on a spectrum and should prompt dose adjustment or a switch to an alternative agent, not self-directed experimentation with unnamed peptide compounds. Supplement co-administration, including omega-3s, is sometimes clinically appropriate alongside GLP-1 therapy due to reduced caloric intake, but is not a standardized protocol.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @pagesix actually say?
Kris Jenner, speaking on the "She MD" podcast, confirmed she tried semaglutide (Ozempic) once, said it made her "really sick" and "nauseous," and then switched to what she calls "a peptide injection" on the advice of a doctor she refers to as "Dr. A." She also said she stacks the injection with supplements including fish oil.
To be precise about what she actually claimed: she didn't call it a treatment for any condition. She didn't name a dose. She framed it as personal experimentation done before Ozempic was a household name, supervised by a physician. That framing is actually more responsible than most celebrity weight-loss disclosures. Still, there's a lot to unpack, particularly the vague "peptide injection" claim and the supplement stacking.
Does the science back this up?
Nausea as a side effect of semaglutide is extremely well-documented, so her experience checks out. The supplement claim is shakier.
GLP-1 receptor agonists like semaglutide cause nausea in roughly 20-44% of users, particularly at the start of treatment or during dose escalation. This is consistently reported across pivotal trials including the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), where gastrointestinal side effects were the most common reason for discontinuation. Jenner saying she felt too sick to work after one trial is consistent with what we know about first-dose GI sensitivity in some patients.
The fish oil recommendation is trickier. Omega-3 supplementation has some evidence for cardiovascular benefit (Bhatt et al., 2019, NEJM, the REDUCE-IT trial), but the idea that it's a standard complement to peptide therapy isn't established in clinical literature. It's not harmful. It's just not proven as a necessary "stack."
What did they get wrong (or right)?
The biggest problem here is the phrase "a peptide injection." This is doing a lot of heavy lifting with no specificity, and that vagueness is a real issue for anyone watching this video hoping to replicate her results.
"Peptide" is a broad biochemical category. It could refer to anything from tirzepatide to BPC-157 to CJC-1295 to dozens of other compounds, some of which are FDA-approved, many of which are not, and some of which have very little human safety data. When a celebrity says a peptide injection "was really great for me" to nearly a million viewers, the lack of specificity isn't humility, it's a gap that can push people toward unregulated products.
What she got right: she had a physician involved, she described a real and documented side effect accurately, and she didn't claim her approach cures anything or that everyone should do what she did. For a celebrity disclosure, that's better than average.
What should you actually know?
GLP-1 intolerance is real and affects a meaningful percentage of patients. It does not mean weight management pharmacotherapy is off the table.
If semaglutide causes intolerable nausea, there are legitimate clinical alternatives. Tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 agonist, has a different tolerability profile for some patients (Jastreboff et al., 2022, NEJM). Dose titration strategies can also reduce GI side effects significantly, and some patients do better with liraglutide. The point is: a bad reaction to one GLP-1 agent should prompt a clinical conversation, not a pivot to unspecified "peptide injections" sourced from wherever.
The supplement angle also deserves scrutiny. Omega-3s, vitamin D, and similar supplements are often added alongside GLP-1 therapy because patients on these medications can lose muscle mass and micronutrient intake may drop alongside caloric intake. That's a legitimate clinical concern (Wilding et al., 2021). But the supplements themselves are not the therapy, and their benefit depends heavily on baseline deficiency and individual health status.
Bottom line: how worried should you be about this video?
Moderately. Jenner's personal account of semaglutide nausea is credible and accurate. The physician-supervised framing is responsible. But "a peptide injection" with no further detail, reaching nearly a million viewers, is the kind of vague celebrity language that sends people down unregulated rabbit holes. If you're watching this and thinking about trying "peptides" for weight management, that conversation needs to happen with a licensed clinician who knows your full history, not a podcast clip.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Kris Jenner and Ozempic: what celebrity use actually tells us, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
Kris Jenner describes a single trial of semaglutide that produced significant nausea and functional impairment, a well-documented side effect affecting up to 44% of users in clinical trials, followed by a switch to an unspecified peptide injection under physician guidance.
FormBlends verdict
Kris Jenner describes a single trial of semaglutide that produced significant nausea and functional impairment, a well-documented side effect affecting up to 44% of users in clinical trials, followed by a switch to an unspecified peptide injection under physician guidance. The clinical takeaway is that GLP-1 intolerance exists on a spectrum and should prompt dose adjustment or a switch to an alternative agent, not self-directed experimentation with unnamed peptide compounds. Supplement co-administration, including omega-3s, is sometimes clinically appropriate alongside GLP-1 therapy due to reduced caloric intake, but is not a standardized protocol.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Kris Jenner describes a single trial of semaglutide that produced significant nausea and functional impairment, a well-documented side effect affecting up to 44% of users in clinical trials, followed by a switch to an unspecified peptide injection under physician guidance. The clinical takeaway is that GLP-1 intolerance exists on a spectrum and should prompt dose adjustment or a switch to an alternative agent, not self-directed experimentation with unnamed peptide compounds. Supplement co-administration, including omega-3s, is sometimes clinically appropriate alongside GLP-1 therapy due to reduced caloric intake, but is not a standardized protocol.
- Up to 44% of semaglutide users experience nausea, and GI side effects were the top reason for discontinuation in the STEP 1 trial (Wilding et al., 2021, NEJM).
- GI intolerance to one GLP-1 agent does not disqualify a patient from the drug class. Tirzepatide showed a distinct tolerability profile in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Up to 44% of semaglutide users experience nausea, and GI side effects were the top reason for discontinuation in the STEP 1 trial (Wilding et al., 2021, NEJM).
- GI intolerance to one GLP-1 agent does not disqualify a patient from the drug class. Tirzepatide showed a distinct tolerability profile in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM).
- 'Peptide injection' is not a medical term. Without knowing the specific compound, no one watching this video can evaluate its safety, efficacy, or legal status.
- Omega-3 supplementation has cardiovascular evidence (REDUCE-IT trial, Bhatt et al., 2019, NEJM) but is not established as a required co-treatment with GLP-1 or peptide therapy.
- Compounded peptide products are not FDA-approved drugs and are not equivalent to brand-name GLP-1 medications. Formulation, dosing accuracy, and sterility vary significantly.
- Patients experiencing significant nausea on GLP-1 therapy should discuss slower dose titration, antiemetic strategies, or alternative agents with their prescribing clinician before stopping.
- Physician involvement in Jenner's regimen is the most responsible element of this disclosure, but celebrity supervision is not a template. Your clinical needs require your own evaluation.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Page Six · TikTok creator
975.2K views on this video
Kris Jenner finally confirms she tried Ozempic after speculation. 🎥: "She MD" podcast
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Page Six, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.